Farahnaz Waissi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Farahnaz Waissi has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Dominique P. V. de Kleijn
Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, the Netherlands
4 shared publications Gert J. de Borst
Department of Vascular Surgery, University Medical Center Utrecht, PO Box 85500, 3508, GA, Utrecht, the Netherlands
3 shared publicationsErik S.G. Stroes
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Meibergdreef 9, Amsterdam, 1105, AZ, the Netherlands
2 shared publications- Gerard Pasterkamp
Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht University , Heidelberglaan 100, 3508, GA, Utrecht
2 shared publications - Jeffrey Kroon
Department of Experimental Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity (AII), Amsterdam, the Netherlands; Atherosclerosis & Aortic Disease, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands; Laboratory of Angiogenesis and Vascular Metabolism, VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium
2 shared publications Johan Kuiper
Leiden Academic Centre for Drug Research, Division of Biotherapeutics, Leiden University
2 shared publications
Latest Publications
- Open Access
- 1 May 2022
- Published by Elsevier in Atherosclerosis
- Vol. 349, 196-203
High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy
- 1 May 2022
- Published by Elsevier in Atherosclerosis
- Vol. 349, 196-203
Open AccessHigh lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy
- Top Cited PapersOpen Access
- 9 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (16) , 1569-1577
Targeted proteomics improves cardiovascular risk prediction in secondary prevention
Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients. Targeted plasma proteomics was performed in two secondary prevention cohorts: the Second Manifestations of ARTerial disease (SMART) cohort (n = 870) and the Athero-Express cohort (n = 700). The primary outcome was recurrent ASCVD (acute myocardial infarction, ischaemic stroke, and cardiovascular death). Machine learning techniques with extreme gradient boosting were used to construct a protein model in the derivation cohort (SMART), which was validated in the Athero-Express cohort and compared with a clinical risk model. Pathway analysis was performed to identify specific pathways in high and low C-reactive protein (CRP) patient subsets. The protein model outperformed the clinical model in both the derivation cohort [area under the curve (AUC): 0.810 vs. 0.750; P < 0.001] and validation cohort (AUC: 0.801 vs. 0.765; P < 0.001), provided significant net reclassification improvement (0.173 in validation cohort) and was well calibrated. In contrast to a clear interleukin-6 signal in high CRP patients, neutrophil-signalling-related proteins were associated with recurrent ASCVD in low CRP patients. A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients. Targeted proteomics in two secondary prevention cohorts outperforms a clinical risk model in terms of discrimination and reclassification. The involvement of neutrophil-related pathways was found in the subset of low C-reactive protein patients. ASCVD, atherosclerotic cardiovascular disease; AUC, area under the curve; NRI, net reclassification improvement; IDI, integrated discrimination index.
- 9 February 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (16) , 1569-1577
Top Cited PapersOpen AccessTargeted proteomics improves cardiovascular risk prediction in secondary prevention
Current risk scores do not accurately identify patients at highest risk of recurrent atherosclerotic cardiovascular disease (ASCVD) in need of more intensive therapeutic interventions. Advances in high-throughput plasma proteomics, analysed with machine learning techniques, may offer new opportunities to further improve risk stratification in these patients. Targeted plasma proteomics was performed in two secondary prevention cohorts: the Second Manifestations of ARTerial disease (SMART) cohort (n = 870) and the Athero-Express cohort (n = 700). The primary outcome was recurrent ASCVD (acute myocardial infarction, ischaemic stroke, and cardiovascular death). Machine learning techniques with extreme gradient boosting were used to construct a protein model in the derivation cohort (SMART), which was validated in the Athero-Express cohort and compared with a clinical risk model. Pathway analysis was performed to identify specific pathways in high and low C-reactive protein (CRP) patient subsets. The protein model outperformed the clinical model in both the derivation cohort [area under the curve (AUC): 0.810 vs. 0.750; P < 0.001] and validation cohort (AUC: 0.801 vs. 0.765; P < 0.001), provided significant net reclassification improvement (0.173 in validation cohort) and was well calibrated. In contrast to a clear interleukin-6 signal in high CRP patients, neutrophil-signalling-related proteins were associated with recurrent ASCVD in low CRP patients. A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients. Targeted proteomics in two secondary prevention cohorts outperforms a clinical risk model in terms of discrimination and reclassification. The involvement of neutrophil-related pathways was found in the subset of low C-reactive protein patients. ASCVD, atherosclerotic cardiovascular disease; AUC, area under the curve; NRI, net reclassification improvement; IDI, integrated discrimination index.
- Open Access
Transcriptomic-based clustering of advanced atherosclerotic plaques identifies subgroups of plaques with differential underlying biology that associate with clinical presentation
Histopathological studies have revealed key processes of atherosclerotic plaque thrombosis. However, the diversity and complexity of lesion types highlight the need for improved sub- phenotyping. We hypothesized that unbiased clustering of plaques based on gene expression results in an alternative categorization of late-stage atherosclerotic lesions. We analyzed the gene expression profiles of 654 advanced human carotid plaques. The unsupervised, transcriptome-driven clustering revealed five dominant plaque types. These novel plaque phenotypes associated with clinical presentation (p<0.001) and showed differences in cellular compositions. Validation in coronary segments showed that the molecular signature of these plaques was linked to coronary ischemia. One of the plaque types with most severe clinical symptoms pointed to both inflammatory and fibrotic cell lineages. This highlighted plaque phenotype showed high expression of genes involved in active inflammatory processes, neutrophil degranulation, matrix turnover, and metabolism. For clinical translation, we did a first promising attempt to identify circulating biomarkers that mark these newly identified plaque phenotypes. In conclusion, the definition of the plaque at risk for a thrombotic event can be fine-tuned by in- depth transcriptomic based phenotyping. These differential plaque phenotypes prove clinically relevant for both carotid and coronary artery plaques and point to differential underlying biology of symptomatic lesions.
Open AccessTranscriptomic-based clustering of advanced atherosclerotic plaques identifies subgroups of plaques with differential underlying biology that associate with clinical presentation
Histopathological studies have revealed key processes of atherosclerotic plaque thrombosis. However, the diversity and complexity of lesion types highlight the need for improved sub- phenotyping. We hypothesized that unbiased clustering of plaques based on gene expression results in an alternative categorization of late-stage atherosclerotic lesions. We analyzed the gene expression profiles of 654 advanced human carotid plaques. The unsupervised, transcriptome-driven clustering revealed five dominant plaque types. These novel plaque phenotypes associated with clinical presentation (p<0.001) and showed differences in cellular compositions. Validation in coronary segments showed that the molecular signature of these plaques was linked to coronary ischemia. One of the plaque types with most severe clinical symptoms pointed to both inflammatory and fibrotic cell lineages. This highlighted plaque phenotype showed high expression of genes involved in active inflammatory processes, neutrophil degranulation, matrix turnover, and metabolism. For clinical translation, we did a first promising attempt to identify circulating biomarkers that mark these newly identified plaque phenotypes. In conclusion, the definition of the plaque at risk for a thrombotic event can be fine-tuned by in- depth transcriptomic based phenotyping. These differential plaque phenotypes prove clinically relevant for both carotid and coronary artery plaques and point to differential underlying biology of symptomatic lesions.
- 1 November 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 62 (5) , 808-815
Mast Cell Distribution in Human Carotid Atherosclerotic Plaque Differs Significantly by Histological Segment
- 1 November 2021
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 62 (5) , 808-815
Mast Cell Distribution in Human Carotid Atherosclerotic Plaque Differs Significantly by Histological Segment
- Open Access
- 15 May 2020
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 4 (5) , 879-885
Sex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia
- 15 May 2020
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 4 (5) , 879-885
Open AccessSex differences in flow cytometry–based platelet reactivity in stable outpatients suspected of myocardial ischemia